Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
Aims Diabetic peripheral neuropathy (DN) is a major complication of type 1 diabetes (T1D), frequently subclinical in youth. Although international pediatric guidelines recommend annual screening, adherence in pediatric care is uncertain. This study aimed to assess DN screening practices in Italian pediatric diabetes centers and identify barriers to implementation. Methods Between December 2024 and May 2025, we conducted a nationwide, cross-sectional survey among Italian centers affiliated with the ISPED Diabetes Study Group. One respondent per center completed a 27-item questionnaire exploring organizational features, DN screening practices, and professional training. Results Forty-eight centers responded to the survey. Written internal protocols for DN screening were available in 22.9% of centers. Only 18.6% reported annual screening, while more than 40% initiated screening only in the presence of symptoms. Recommended criteria (age >= 11 years and 2-5 years diabetes duration) were applied by 31.3% of centers. Clinical neurological examination was widely adopted (95.8%), whereas nerve conduction studies (29.2%) and the Michigan Neuropathy Screening Instrument (14.6%) were rarely used. Notably, 89.6% of respondents had never received formal training in DN screening. Centers where pediatric diabetologists personally conducted the assessment were more likely to adhere to annual screening (p = 0.010). Conclusions Screening for DN in Italian pediatric diabetology is inconsistent and frequently delayed, contributing to probable underrecognition of early neuropathic changes. Strengthening professional awareness, promoting structured training, and implementing harmonized national protocols are essential steps to ensure timely identification and equitable care for children and adolescents with T1D.
Screening practices for diabetic peripheral neuropathy in pediatric type 1 diabetes: a nationwide survey by the ISPED Diabetes Study Group / Bombaci, B., Bassi, M., Castorani, V., Di Candia, F., Ferrari, M., Martino, M., Zagaroli, L., Marigliano, M., Bonfanti, R., Albino, C.A., Aloe, M., Anzelotti, M.T., Arnaldi, C., Barbetti, F., Bassi, M., Berioli, M.G., Bernardini, L., Bertelli, E., Biagioni, M., Bobbio, A., et al.. - In: ACTA DIABETOLOGICA. - ISSN 1432-5233. - 2026:(2026). [10.1007/s00592-026-02646-z]
Screening practices for diabetic peripheral neuropathy in pediatric type 1 diabetes: a nationwide survey by the ISPED Diabetes Study Group
Aims Diabetic peripheral neuropathy (DN) is a major complication of type 1 diabetes (T1D), frequently subclinical in youth. Although international pediatric guidelines recommend annual screening, adherence in pediatric care is uncertain. This study aimed to assess DN screening practices in Italian pediatric diabetes centers and identify barriers to implementation. Methods Between December 2024 and May 2025, we conducted a nationwide, cross-sectional survey among Italian centers affiliated with the ISPED Diabetes Study Group. One respondent per center completed a 27-item questionnaire exploring organizational features, DN screening practices, and professional training. Results Forty-eight centers responded to the survey. Written internal protocols for DN screening were available in 22.9% of centers. Only 18.6% reported annual screening, while more than 40% initiated screening only in the presence of symptoms. Recommended criteria (age >= 11 years and 2-5 years diabetes duration) were applied by 31.3% of centers. Clinical neurological examination was widely adopted (95.8%), whereas nerve conduction studies (29.2%) and the Michigan Neuropathy Screening Instrument (14.6%) were rarely used. Notably, 89.6% of respondents had never received formal training in DN screening. Centers where pediatric diabetologists personally conducted the assessment were more likely to adhere to annual screening (p = 0.010). Conclusions Screening for DN in Italian pediatric diabetology is inconsistent and frequently delayed, contributing to probable underrecognition of early neuropathic changes. Strengthening professional awareness, promoting structured training, and implementing harmonized national protocols are essential steps to ensure timely identification and equitable care for children and adolescents with T1D.
Screening practices for diabetic peripheral neuropathy in pediatric type 1 diabetes: a nationwide survey by the ISPED Diabetes Study Group / Bombaci, B., Bassi, M., Castorani, V., Di Candia, F., Ferrari, M., Martino, M., Zagaroli, L., Marigliano, M., Bonfanti, R., Albino, C.A., Aloe, M., Anzelotti, M.T., Arnaldi, C., Barbetti, F., Bassi, M., Berioli, M.G., Bernardini, L., Bertelli, E., Biagioni, M., Bobbio, A., et al.. - In: ACTA DIABETOLOGICA. - ISSN 1432-5233. - 2026:(2026). [10.1007/s00592-026-02646-z]
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/489171
Citazioni
1
ND
0
ND
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.